10-K: Cadrenal Therapeutics Faces Going Concern Warning Amidst Pipeline Progress

Cadrenal Therapeutics reports increased losses and a significant cash burn in its 2025 annual report, raising substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidate CAD-1005 towards a pivotal Phase 3 trial.

Summary

• Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions.
• The company's primary strategic focus has shifted to CAD-1005, a first-in-class selective 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT).
• An End-of-Phase 2 (EOP2) meeting with the FDA on March 26, 2026, clarified a potential registrational path for the planned Phase 3 pivotal trial of CAD-1005 in HIT patients.
• CAD-1005 holds Orphan Drug Designation (ODD) and Fast Track designation from the FDA for HIT, and orphan designation from the EMA for platelet-activating factor 4 disorders.
• The company acquired the 12-LOX platform assets, including CAD-1005, from Veralox Therapeutics in December 2025 for $200,000 cash, assumed liabilities, up to $15 million in contingent milestones, and 5% royalties on net sales.
• The broader pipeline includes tecarfarin, an oral vitamin K antagonist for patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a Phase 2-ready intravenous (IV) Factor XIa inhibitor for acute care settings.
• The eXIthera assets, including frunexian, were acquired in September 2025 for $50,000 cash, assumed liabilities, up to $15 million in contingent milestones, and 2% royalties on net sales (plus 50% of Haisco royalties).
• Cadrenal reported a net loss of $13.2 million for the fiscal year ended December 31, 2025, an increase from $10.6 million in 2024.
• Cash and cash equivalents decreased significantly to $4.0 million as of December 31, 2025, from $10.0 million at the end of 2024.
• Cash used in operating activities for 2025 was $12.6 million, up from $7.4 million in 2024.
• The company's auditors included an explanatory paragraph in their report, raising substantial doubt about Cadrenal's ability to continue as a going concern.
• Commencement of the CAD-1005 Phase 3 trial is contingent on obtaining sufficient financing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk, early-stage biopharmaceutical company facing significant financial challenges and clinical uncertainties, despite some promising drug candidates and regulatory designations. The going concern warning and increased losses are major concerns.

Positives

• A potential registrational path for the CAD-1005 Phase 3 pivotal trial in HIT patients was clarified with the FDA.
• CAD-1005 has received Orphan Drug Designation and Fast Track designation from the FDA, and orphan designation from the EMA for HIT, which can expedite development and provide market exclusivity.
• Tecarfarin has Orphan Drug Designation and Fast Track designation from the FDA for the prevention of systemic thromboembolism in ESKD patients with AFib and in patients with implanted LVADs.
• A Collaboration Agreement was signed with Abbott Global Enterprises Limited to support the development of tecarfarin in patients with an implanted HeartMate 3 LVAD.
• CAD-1005 Phase 1 clinical studies in over 100 healthy volunteers demonstrated it was well tolerated with no serious adverse events.
• Preclinical data for CAD-1005 showed effectiveness in blocking platelet activation, clot formation, and thrombosis in animal models without increasing bleeding risk.
• Frunexian Phase 1 studies indicated it was generally well tolerated with no serious adverse events and exhibited dose-proportional inhibition of Factor XIa activity.
• Management estimates a peak annual market revenue potential of approximately $825 million for CAD-1005 in HIT and a combined peak annual U.S. market revenue potential of approximately $2 billion for tecarfarin and frunexian in orphan and high-risk cardiovascular conditions.
• Manufacturing of tecarfarin drug product has been completed in accordance with current good manufacturing practices (cGMP).

Negatives

• Net loss increased by 23% to $13.2 million in 2025 from $10.6 million in 2024.
• Cash and cash equivalents decreased by 60% from $10.0 million at December 31, 2024, to $4.0 million at December 31, 2025.
• Cash used in operating activities increased by 71% from $7.4 million in 2024 to $12.6 million in 2025.
• The company's auditors issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• The CAD-1005 Phase 2 trial failed to meet its primary endpoint of platelet count recovery rate and was terminated early, enrolling only 22 out of a planned 60 participants.
• Commencement of the CAD-1005 Phase 3 trial is dependent on obtaining sufficient financing.
• Tecarfarin's issued U.S. patents expired in 2024, and its foreign patents expired in April 2025, significantly reducing its intellectual property protection.
• The company has a limited operating history and has not yet conducted its own clinical trials.
• Heavy reliance on third-party manufacturers and Contract Development and Manufacturing Organizations (CDMOs) for drug supply, with no long-term supply agreements in place for CAD-1005 or frunexian.
• General and administrative expenses increased by 39% ($2.6 million) in 2025, primarily due to costs associated with operating as a public company.
• Interest and dividend income decreased by 28% ($85,436) in 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows.
• The company will need to raise additional capital, which may result in dilution for existing stockholders or restrictive debt covenants.
• Future success depends heavily on FDA review of the Phase 3 trial protocol and commencement of the Phase 3 clinical trial, which is subject to additional FDA comments and sufficient financing.
• The 12-LOX platform assets are subject to significant clinical risks, and the observed benefit in thrombotic events in the CAD-1005 Phase 2 study may be due to chance as the study was not powered for statistical significance and was terminated early.
• Inadequate funding for the FDA, SEC, and other government agencies, including from government shutdowns, could negatively impact business operations and regulatory timelines.
• The business is substantially dependent on the Old Dominion License Agreement for CAD-1005, and its termination, non-renewal, or failure to maintain it could materially and adversely affect the business.
• All current data for product candidates are results of clinical trials conducted by third parties, and there is no guarantee these results can be replicated or that the trials were fully compliant with regulations.
• Development efforts may not generate data sufficient to support regulatory approval, and the FDA or EMA may require additional clinical testing.
• Even if regulatory approval is obtained, market acceptance by physicians, patients, healthcare payors, and others in the medical community is not assured.
• The company has never submitted a New Drug Application (NDA) to the FDA or comparable applications to other regulatory authorities.
• Any product candidate, if approved for commercialization, will remain subject to ongoing regulatory obligations and other restrictions, including potential withdrawal from the market or penalties for non-compliance.
• Reliance on third-party manufacturers exposes the company to supply disruptions, regulatory compliance risks, and limited control over operations.
• The company faces substantial competition from major pharmaceutical companies with significantly greater resources and established products.
• Serious adverse effects identified with product candidates could lead to modification or abandonment of development, discontinuation of sales, or changes in labeling.
• Recently enacted and future legislation (e.g., Inflation Reduction Act, Affordable Care Act) may increase the difficulty and cost of obtaining marketing approval and commercialization, and affect product pricing.
• The company may be subject to civil or criminal penalties if it violates healthcare fraud and abuse laws or government price reporting laws.
• The ability to generate product revenues will be diminished if products sell for inadequate prices or patients are unable to obtain adequate levels of reimbursement.
• The company will rely on third parties and consultants to conduct all clinical trials, and their failure to perform could delay or prevent regulatory approval.
• The company currently lacks internal distribution, marketing, support, and sales capabilities and plans to rely on third-party partners, which could limit revenue generation.
• Employees, contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards.
• Failure to attract and keep senior management and key scientific personnel could impede successful product development and commercialization.
• The company will need to increase the size of its organization and may experience difficulties in managing this growth.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization of future products.
• Computer system failures, cybersecurity attacks, and data leakage risks could disrupt operations and harm reputation.
• The use of artificial intelligence in research, development, and commercial activities presents operational, regulatory, ethical, and reputational risks.
• Acquisitions of other businesses or formation of joint ventures could harm operating results, dilute stockholders' ownership, increase debt, or incur significant expense.
• Declining general economic or business conditions, including inflation and geopolitical instability, may negatively impact the business.
• The company may be unable to obtain and maintain sufficient exclusivity or patent protection for its product candidates; all issued U.S. and foreign patents for tecarfarin expired in 2024 and 2025.
• Involvement in intellectual property lawsuits could be expensive, time-consuming, and unsuccessful.
• Changes to patent law in the United States and other jurisdictions could diminish the value of patents.
• Failure to comply with governmental patent agency requirements could reduce or eliminate patent protection.
• The company may not be able to enforce its intellectual property rights throughout the world.
• The company may be subject to claims by third parties asserting misappropriation of their intellectual property.
• An active public trading market for the Common Stock may not be maintained, and the company cannot be assured of maintaining its listing on the Nasdaq Capital Market (previously received a non-compliance notice, regained compliance after reverse split, but new rule changes are proposed).
• The company's stock price has been extremely volatile and may continue to be so, potentially leading to substantial losses for investors.
• Even if product candidates receive FDA approval, there is no guarantee that the trading price of the Common Stock will increase.
• If favorable research or reports about the business are not published, or if analysts issue inaccurate or unfavorable commentary, the stock price could decline.
• The Chief Executive Officer can exercise significant control over the company (beneficially owns approximately 17% of outstanding capital stock).
• Future sales and issuances of Common Stock or rights to purchase Common Stock could result in dilution and depress the market price.
• Anti-takeover provisions in charter documents and under Delaware law could make an acquisition more difficult.
• Exclusive forum provisions in charter documents could result in increased costs for stockholders to bring claims and limit their ability to obtain a favorable judicial forum.
• Claims for indemnification by directors and officers may reduce available funds to satisfy third-party claims.
• The company does not intend to pay dividends in the foreseeable future, so returns depend on stock price appreciation.
• Certain members of the management team have limited experience managing a public company.
• The company has incurred significant increased costs as a result of operating as a public company and expects additional costs when clinical trials commence.
• As an emerging growth company and smaller reporting company, the company may avail itself of reduced disclosure requirements or extended transition periods for accounting standards, which may make its Common Stock less attractive to investors.
• There is no public market for the outstanding warrants, limiting their liquidity.

Future Outlook

The company plans to advance CAD-1005 into a pivotal Phase 3 clinical trial for HIT, contingent on receiving final FDA meeting minutes and securing sufficient financing. If approved, the intention is to expand CAD-1005's label for additional applications such as diabetes, atherosclerosis, and chronic vascular inflammation. Furthermore, the company is evaluating opportunities for additional Phase 2/3 trials for tecarfarin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib), and/or stable left ventricular assist device (LVAD) patients.

Management Comments

• Our overarching goal at Cadrenal is to advance novel therapies for life-threatening immune and thrombotic conditions.
• Our current primary focus is advancing a transformative therapeutic approach for the treatment of HIT.
• We believe that our existing cash and cash equivalents will not be sufficient to meet our anticipated cash requirements for the next twelve months.
• To meet anticipated funding needs, we plan to seek additional capital through strategic partnerships, equity offerings, and/or debt financings.

Industry Context

StockSavvy.ai notes that Cadrenal operates in the highly competitive biopharmaceutical sector, specifically targeting cardiovascular and immune-mediated thrombotic conditions. This area has seen relative underinvestment in drug development over the past two decades despite significant global burden. The company's strategy to focus on novel mechanisms like 12-LOX inhibition for HIT, where existing therapies primarily address thrombotic complications, represents a differentiated approach. However, the industry faces high costs for clinical trials, stringent regulatory requirements, and intense competition from established pharmaceutical giants with greater resources and existing market dominance. The expiration of tecarfarin's patents highlights the critical importance of intellectual property in this capital-intensive industry.

Comparison to Industry Standards

• Warfarin, a dominant Vitamin K Antagonist (VKA), has been in use since the early 1950s, with which physicians and healthcare organizations have 60 years of familiarity. Tecarfarin is designed to overcome warfarin's metabolic factors and has shown more reliable anticoagulation in certain patient subgroups.
• Direct Oral Anticoagulants (DOACs) like Pradaxa, Xarelto, Eliquis, and Savaysa are generally more rapid in onset/offset and have fewer drug-to-drug interactions than VKAs, but are contraindicated or not recommended for specific patient populations such as those with LVADs or ESKD/AFib, which are tecarfarin's target indications.
• The ARIES-HM3 study, involving LVAD patients, showed an average Time in Therapeutic Range (TTR) of only 56% with warfarin, which is below the benchmark of 70% for well-controlled anticoagulation. In contrast, tecarfarin's EMBRACE-AC trial showed a mean TTR of 72.3% (vs. 71.5% for warfarin), and a post-hoc analysis excluding off-therapy INR values showed a significantly higher TTR for tecarfarin (68.8%) compared to warfarin (66.4%).
• In the EMBRACE-AC trial, major bleeding events for both tecarfarin (1.6%) and warfarin were lower compared to prior anticoagulation trials. Notably, there were no thrombotic events among tecarfarin-treated patients, compared to five in the warfarin group.
• Frunexian is highlighted as the only IV Factor XIa inhibitor in clinical development targeting acute/critical care, differentiating it from widely used inpatient parenteral anticoagulants such as unfractionated heparin, LMW heparin, direct thrombin antagonists (bivalirudin, argatroban), and direct Xa inhibitors (fondaparinux).

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• Other than compensation arrangements with directors and executive officers, the company has not engaged in any material related party transactions since January 1, 2024, where the amount involved exceeded $120,000 or 1% of the average of total assets.

Stakeholder Impact

• Shareholders face potential for significant dilution from future capital raises, continued stock price volatility, and the risk of delisting from Nasdaq. There is no intention to pay dividends in the foreseeable future, and limited control due to concentrated ownership and anti-takeover provisions.
• Employees are subject to the company's need to attract and retain senior management and key scientific personnel, potential difficulties in managing organizational growth, and the risk of misconduct.
• Customers and patients could benefit from potential novel therapies for life-threatening immune and thrombotic conditions (CAD-1005 for HIT, tecarfarin for ESKD/AFib/LVADs, frunexian for acute care), but face the risk of product candidates failing clinical trials or not receiving regulatory approval, as well as the potential for serious adverse effects.
• Suppliers and creditors are impacted by the company's reliance on third-party manufacturers and CDMOs for drug supply, potential for supply disruptions, and the company's going concern uncertainty, which could affect its ability to secure favorable terms.
• Regulatory bodies will continue to interact with the company for clinical trial protocols and approvals, ensuring compliance with extensive regulations (cGMP, GCP, fraud and abuse laws, price reporting), with potential for sanctions or withdrawal of approvals for non-compliance.

Next Steps

• Submit the Phase 3 trial protocol for CAD-1005 to the FDA for review and await final meeting minutes and comments.
• Obtain sufficient financing to commence the pivotal Phase 3 clinical trial for CAD-1005.
• Seek to expand the label for CAD-1005 through additional filings for indications such as diabetes, atherosclerosis, and chronic vascular inflammation.
• Evaluate opportunities for additional Phase 2/3 trials for tecarfarin in ESKD patients with AFib and/or stable LVAD patients.
• Execute contracts with third-party CDMOs for the supply of drug substance and drug product for acquired drug candidates (eXIthera and Veralox assets).
• Potentially hire and train a small, dedicated salesforce for U.S. commercialization, and enter distribution/commercial partnerships for other markets, if products are approved.
• Continue to increase the size of the organization and expand managerial, operational, and finance resources.
• Apply for patent term extensions for FDA-approved products, if available.
• Apply for five years of data exclusivity for NDA-approved products.
• Conduct post-approval trials (Phase 4) if required by the FDA.
• Comply with ongoing regulatory obligations, including post-market surveillance and cGMP requirements.
• Continue to monitor and adjust regulatory strategies in response to potential government shutdowns or changes in funding.
• Conduct annual assessment of cyber risk management processes and controls.
• The Board of Directors will review cybersecurity risks at least annually as part of corporate risk oversight.
• The Audit Committee will review the adequacy of computerized information system controls and security annually.
• The management team will brief the Audit Committee on cyber vulnerabilities and program effectiveness annually.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a significant increase in net loss, a drastic reduction in cash reserves, and an explicit 'going concern' warning from its auditors. While it has promising drug candidates with orphan and fast-track designations, the lead candidate CAD-1005 failed its primary endpoint in Phase 2 and requires substantial future financing for a pivotal Phase 3 trial. Furthermore, key patents for tecarfarin have expired, and the company has a limited operating history in conducting its own clinical trials and commercialization. These factors, combined with high competition and regulatory hurdles, present an extremely high-risk profile, making the stock a 'sell' for seasoned investors until significant financial stability and clear clinical success are demonstrated.

Keywords

Biopharmaceutical, Thrombosis, Heparin-Induced Thrombocytopenia, 12-LOX inhibitor, CAD-1005, Tecarfarin, Frunexian, Anticoagulant, Orphan Drug, Fast Track, Clinical Trials, FDA, EMA, Drug Development, Cardiovascular, SEC Filing, 10-K, Biotech, Pharmaceutical, Going Concern